Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASPH | Q12797 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018797 | 1.00 | ASPH (0.45) | ASPHTSHRHSD17B10KDM4EKDM8 | |
| Nitrous Acid SCHEMBL28850943 | 0.94 | ASPH (0.41) | ASPHTSHRHSD17B10KDM4EKDM8 | |
| SCHEMBL19481003 | 0.86 | ASPH (0.45) | ASPHTSHRHSD17B10KDM4EKDM8 | |
| SCHEMBL30536915 | 0.86 | ASPH (0.45) | ASPHTSHRHSD17B10KDM4EKDM8 | |
| SCHEMBL2987993 | 0.84 | KMT2A (0.38) | ASPHTSHRCA2 | |
| SCHEMBL29664135 | 0.84 | KMT2A (0.38) | ASPHTSHRCA2 | |
| SCHEMBL22899985 | 0.82 | HSD17B10 (0.41) | ASPHTSHRHSD17B10KDM4EKDM8 | |
| SCHEMBL17293016 | 0.80 | SOS1 (0.47) | TSHRKDM4ENOTUM | |
| SCHEMBL30824163 | 0.80 | SOS1 (0.47) | TSHRKDM4ENOTUM | |
| SCHEMBL2394618 | 0.80 | ASPH (0.59) | ASPHKDM4EKDM8DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-27 | — | — | US | disclosed |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118745185-A | Imidazopyrimidines as EED inhibitors and use thereof | 密歇根大学董事会 | 2024-10-08 | — | — | CN | disclosed |
| US-20240316051-A1 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-09-26 | — | — | US | disclosed |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8263588-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | disclosed |
| CN-101678007-A | gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2155194-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008124610-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124614-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ASPH 1287/4885TSHR 56/4885HSD17B10 653/4885 |
| US-20240316051-A1 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | EED, EML4, KIT | ASPH 1193/4885TSHR 4011/4885HSD17B10 2787/4885 |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | EED, EEF1D, EEF1A1 | ASPH 3171/4885TSHR 2221/4885HSD17B10 1688/4885 |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ASPH 1287/4885TSHR 56/4885HSD17B10 653/4885 |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ASPH 1304/4885TSHR 58/4885HSD17B10 606/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | ASPH 3171/4885TSHR 2221/4885HSD17B10 1688/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | ASPH 1159/4885TSHR 4501/4885HSD17B10 3168/4885 |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ASPH 1304/4885TSHR 58/4885HSD17B10 606/4885 |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ASPH 1267/4885TSHR 57/4885HSD17B10 645/4885 |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | CBR1, CBR3, NOX1 | ASPH 2565/4885TSHR 2818/4885HSD17B10 541/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ASPH 2596/4885TSHR 3163/4885HSD17B10 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.